Governance

EBE Board Members 2016-2018

  • Eduardo Bravo

    Eduardo Bravo

    EBE President
    TiGenix
    Chief Executive Officer
    Eduardo Bravo

    Eduardo Bravo

    EBE President
    TiGenix
    Chief Executive Officer

    Eduardo Bravo, CEO of TiGenix, who previously served as EBE Vice-President. Mr Bravo has more than twenty-five years experience in the biopharmaceutical industry. Since 2011 he is CEO of TiGenix. Before TiGenix, he was CEO of Cellerix and held senior management positions at Sanofi-Aventis, including Vice President for Latin America. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). He is also a member of the Executive Committee of the Alliance for Regenerative Medicine (ARM). Mr. Bravo brings invaluable experience from the field of advanced therapies, bridging the gap between the lab and personalised medicines supported by a thriving innovation ecosystem. Mr Bravo is the EBE President since June 2016.

  • Andrea Chiesi

    Andrea Chiesi

    EBE Vice-President
    Chiesi Farmaceutici
    VP Holostem Advanced Therapies, Director R&D Project Portfolio Management
    Andrea Chiesi

    Andrea Chiesi

    EBE Vice-President
    Chiesi Farmaceutici
    VP Holostem Advanced Therapies, Director R&D Project Portfolio Management

    Trained as a pharmaceutical chemist and technologist, Andrea Chiesi has more than 20 years’ experience in the pharmaceutical and biotechnology sector. Starting as a lab analyst at the Chiesi Group, he came to the lead the Pharmaceutical Engineering Unit, before becoming a Project Leader, where he was responsible of taking to market a new Dry Powder Inhaler. In 1999 he was appointed Director of R&D Planning and Control of the Chiesi R&D. In 2008, with G.Pellegrini and M.DeLuca, Andrea has founded Holostem Terapie Avanzate srl, a spin-off company of the University of Modena of which he is the CEO. Holostem specialises in development and manufacturing of advanced therapies, with a focus on epithelia. Mr Chiesi is the EBE Vice-President since June 2016.

  • Didier Malherbe

    Didier Malherbe

    EBE Treasurer
    UCB
    Vice President & Head of Public Affairs UCB and General Manager UCB Belgium
    Didier Malherbe

    Didier Malherbe

    EBE Treasurer
    UCB
    Vice President & Head of Public Affairs UCB and General Manager UCB Belgium

    Didier Malherbe joined the UCB Group in 2006, as Vice President Public Affairs and Managing Director of UCB Belgium. Having a degree in law from UCL, he started his career as a consultant and then chief of cabinet at the Walloon, Brussels and federal governments. He joined the private sector in 1993 and worked successively for Spadel, Bellsouth (US) before taking the direction of the External Relations of the FEB. He is also the founder of the European Student Fair and of the European Business Summit. Didier Malherbe is President of Essenscia Brussels, Director of the Union Wallonne des Entreprises (UWE), BECI, UCL, BioWin, Welbio and the Belgian Foreign Trade Agency.

  • Roberto Gradnik

    Roberto Gradnik

    Ixaltis
    Chief Executive Officer
    Roberto Gradnik

    Roberto Gradnik

    Ixaltis
    Chief Executive Officer

    Trained as a physician, Roberto Gradnik has more than 25 years’ experience in the pharmaceutical and biotechnology sector. After holding various positions with the Knoll Group (a subsidiary of the BASF Group), including that of Vice-President International Marketing Cardiovascular, he joined the Serono Group in 1999 as Italy’s General Manager and Head of Southern European Subsidiaries. He was then appointed Executive Vice-President for Europe, in charge of all European markets, and a member of the Executive Committee. He continued in the same position for Merck Serono after the acquisition of Serono by Merck AG. More recently, he was appointed Executive Vice-President, Global Business Unit for Neurodegenerative Diseases for Merck Serono. He was President of Assobiotec (Italian association of the biotech industry) 05/2004 - 05/2010. From January 1st, 2012 he has been Chief Executive Officer of Stallergenes, a European biopharmaceutical company dedicated to the immunotherapy of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma. More recently Roberto Gradnik serves as a strategic advisor to the CEO of Stallergenes and is a board member of Stallergenes. He has also been appointed as President of European Biopharmaceutical Enterprises, EBE since July 2012.

  • Eugenio  Aringhieri

    Eugenio Aringhieri

    Dompé
    Chief Executive Officer
    Eugenio  Aringhieri

    Eugenio Aringhieri

    Dompé
    Chief Executive Officer

    Since 2007, in line with the wishes of its owner, he has promoted the company’s functional reorganisation and given impulse to its industrial strategy with the aim of making the Group an internationally recognised science-based company. To this end, in 2008, he consolidated its partnership with Amgen by creating Amgen Dompé, a parithetic joint venture of which he was Chief Executive Officer, and established the strategic programme and priority objectives of Biogen Dompé, a parithetic joint venture with Biogen Idec, the world’s leading biotech company, thus consolidating their initial marketing agreement into a partnership by creating a new company in Italy and Switzerland of wich he was CEO. He also further strengthened the Group’s commitment to research, and promoted a strategy of investing in companies capable of dynamically contributing to therapeutic innovation. In 2010, he was nominated Vice-President of the Board of Directors of Philogen, an Italo-Swiss biotech company dedicated to developing products for the treatment of cancer, rheumatoid arthritis and some eye diseases, of which Dompé is the leading shareholder. In 2011, he joined the Board of Directors of AAA (Advanced Accelerator Applications), a leader in the field of molecular medicine that specialises in R&D, the production of radiopharmaceuticals for molecular imaging, and personalised medicine. In the same year, he became President and Chief Executive Officer of Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available, whose acquisition was completed in February 2012. At the beginning of his career Eugenio Aringhieri worked in different multinational companies, such as in the Sales and Marketing field of Johnson & Johnson and Rhône-Poulenc, focused in Oncology and CNS therapeutic areas. In 2014, he was nominated Farmindustria's representative on the National Committee for Biosafety, the Biotechnologies and the Life Sciences instituted by the office of the Italian Prime Minister. In 2013, re-elected President of Farmindustria’s Biotech Group for a second consecutive mandate. Since 2008, member of the International Board of European Bopharmaceutical Enterprises (EBE). Since 2000, member of the Board of Governors of Farmindustria.

  • Christophe  Jean

    Christophe Jean

    Ipsen
    Executive Vice President, Corporate Strategy, Business Development, Alliances and M&A
    Christophe  Jean

    Christophe Jean

    Ipsen
    Executive Vice President, Corporate Strategy, Business Development, Alliances and M&A

    Christophe Jean joined the Ipsen Group in September 2002 as Executive Vice-President, Chief Operating Officer. He was in charge of all commercial operations and medical affairs worldwide as well as Ipsen’s therapeutic area franchises until his appointment as Executive Vice-President, Corporate Strategy, Business Development, Alliances and M&A in October 2013. Christophe Jean remains a member of the Ipsen Group Executive Committee. Graduated from Harvard Business School, Christophe Jean joined the pharmaceutical industry with Ciba-Geigy where he occupied several marketing and general management positions in Europe and Latin America. Subsequently he was appointed Head of Finance and IT worldwide and Member of the Pharma Executive Committee in Basel. After the merger that formed Novartis, he became President Europe, Middle East and Africa for the Pharmaceuticals Division. In 2000, he became President and CEO for the pharmaceutical activities of the Pierre Fabre Group before joining the Ipsen Group. He is a member of the Supervisory Board of Diaxonhit and a member of the EBE Board (European
    Biopharmaceutical Enterprises).

  • Ahmed Bouzidi

    Ahmed Bouzidi

    Vaxeal
    Chief Executive Officer
    Ahmed Bouzidi

    Ahmed Bouzidi

    Vaxeal
    Chief Executive Officer

    Ahmed Bouzidi, Ph.D., serves as the Chief Executive Officer and Director of Vaxeal Holding SA. He previously founded SEDAC-Therapeutics inc. (FR, US), a leading biotech pioneer in peptidebased therapeutic vaccines, and served as its CEO (exit by LBO). He also founded and managed Biophysiomics Holding inc. (M&A by Chengdu Kuachang Science & Technology, CN). Dr. Bouzidi held senior advisory positions with Chinese pharmaceutical companies and public institutions, and worked 10 years as senior researcher at the LFB (FR). He serves as a Board Member of Vaccines Europe and the European Biopharmaceutical Enterprises. Dr. Bouzidi holds a Master degree in Animal Biology from University of Lille (FR). He also received a PhD in Cellular Biology and an MBA in Finance from University of New Hampshire, Durham (USA).

  • Jochen Maas

    Jochen Maas

    Sanofi Aventis Germany
    General Manager R&D
    Jochen Maas

    Jochen Maas

    Sanofi Aventis Germany
    General Manager R&D

    Jochen Maas is appointed General Manager, Research & Development (R&D) at Sanofi-Aventis Deutschland GmbH, as of October 1st, 2010, based in Frankfurt. He is a member of the Global R&D Management Board and of the German Management Board. He was appointed as head of the German hub R&D organization in 2012. Jochen has huge experience in all phases of the R&D value chain. He started his career in PK, then he expanded his responsibilities to preclinical Development, preclinical and clinical Development and Research & Development. Afterwards, he was responsible for Global Research & Development in the Diabetes Division and acted as Vice President R&D Europe at sanofi-aventis. Jochen also lectures in pharmacokinetics and administering medication as a professor at Gießen-Friedberg University of Applied Sciences. He is a biologist and veterinarian. He has a doctorate in veterinary medicine including a specification in Radiology. He studied at the Universities of Zurich, Heidelberg and Munich. After joining the Group in 1992 as head of the pharmacokinetics laboratory, he held various R&D management positions in Germany and France. Jochen is married and has three sons.

  • Herb Riband

    Herb Riband

    Amgen
    Vice President Value, Access & Policy International
    Herb Riband

    Herb Riband

    Amgen
    Vice President Value, Access & Policy International

     Herb Riband joined Amgen in 2012, based at the company’s European headquarters in Zug, Switzerland. 

    In this role he is responsible for leading Amgen’s value, access and policy function in regions outside of the United States. Deliverables include anticipating and addressing the company’s market access and policy needs across multiple jurisdictions, operating as a senior leader of a global function and the European management committee. Responsibilities include: 

    ⇒ Overseeing Amgen’s access, health economics and strategic pricing activities in Europe, Russia, Turkey, Middle East and Africa. 

    ⇒ Ensuring the development of strategic access and health economic evidence generation plans for pipeline products, and the execution of access activities for marketed products. 

    ⇒ Coordinating healthcare policy and government affairs activities in regions outside of the United States, focusing on priority issues (biosimilars, HTA, pricing & reimbursement and access to R&D innovation), working cross-functionally within Amgen and via industry associations. 

    ⇒ Building credible relationships with a diverse set of external stakeholders including governments, payers, providers, patient advocacy groups and leading NGOs. 

    ⇒ Developing talent and building internal market access and government affairs capabilities in Amgen regions and affiliates. 

     

    Prior to joining Amgen Mr. Riband worked with Medtronic, Inc. for 13 years in a variety of roles, including Vice President External Affairs International for Medtronic's International region (comprising all markets outside the United States) with responsibility for market access, reimbursement, healthcare policy and corporate philanthropy activities. In connection with this role, Mr. Riband was active in Eucomed, the European medical technology industry association, serving as Chair of the Eucomed Public Affairs Network and on Eucomed’s International Affairs Group and Corporate Advisory Council. Mr. Riband also served as a member of two industry/government bodies, the UK Ministerial Medical Technology Strategy Group (MMTSG) and the Geneva-based Council for Multilateral Business Diplomacy (CMBD). 

    Prior to joining Medtronic, Mr. Riband held a variety of international business, consulting and legal roles in London, Madrid, Connecticut and Washington D.C. He has lived and worked in Europe for over 22 years and is a citizen of the United States and (expected in October 2014) Switzerland. 

    A native of Philadelphia, Pennsylvania, Mr. Riband received degrees from Cornell University and the University of Michigan Law School.

  • François Martelet

    François Martelet

    NetScientific
    CEO
    François Martelet

    François Martelet

    NetScientific
    CEO

    Dr. Martelet joined the NetScientific Group on 8 June 2015.  

    Most recently, Dr. Martelet has served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

     Prior to this, Dr Martelet served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly. 

  • Michele Antonelli

    Michele Antonelli

    Stallergenes SAS
    President Stallergenes SAS and Executive Vice President, Head of Europe and International, Stallergenes-Greer
    Michele Antonelli

    Michele Antonelli

    Stallergenes SAS
    President Stallergenes SAS and Executive Vice President, Head of Europe and International, Stallergenes-Greer

    Michele Antonelli was appointed President of Stallergenes SAS and Executive Vice President, Head of Europe & International at Stallergenes-Greer in 2016. Michele has more than 20 years of international experience in the biopharmaceutical industry, with extensive expertise in both manufacturing and commercial. He joined

    Stallergenes SAS in November 2015 as Executive Vice President, Head of International Operations. Michele previously worked at UCB, where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities. Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.

  • Nicola Beaucamp

    Nicola Beaucamp

    Roche Diagnostics GmbH
    Head of Process Research Large Molecule Research, Pharma Research and Early Development
    Nicola Beaucamp

    Nicola Beaucamp

    Roche Diagnostics GmbH
    Head of Process Research Large Molecule Research, Pharma Research and Early Development

    Ms Nicola Beaucamp was appointed Head of Process Research in Pharma Research & Early Development as of September 1st, 2015, based in Roche Innovation Center Munich, Germany. With this senior management position she is responsible for pre-clinical and clinical supply up to phase I for the Roche Research unit in Europe. With more than 15 years experience in biotechnology and pharmaceutical industry, Ms Beaucamp has huge know-how in all phases of the R&D value chain. She is biologist by training and did her academic studies at the University of Regensburg, Germany where she obtained her PhD at the Institute of Biophysics and biophysical Chemistry in 1996. After two years at the Molecular Neurobiology Group at the University of Bristol, UK, Ms Beaucamp returned to Germany to start her career as group leader in a Biotech Company before joining Roche beginning of 2005.

    Since then she successfully led a group and from 2007 a department in Process Research before she was appointed to her current position. An important part of her activities fostered development of accelerated processes and technology innovation. She is member of the Roche Global Technology Steering Committee. In addition to her technology focus, Ms Beaucamp successfully led Inflammation and Oncology programs up to entry into clinics. Being a committed senior leader, Ms Beaucamp was and is member of several global strategic and decision making committees

EBE Working Groups Leadership

  • Advanced Therapies (joint Working Group with EFPIA)

    Chair: Maria Pascual, TiGenix
    Vice Chair: Esther Choi, Bristol-Myers Squibb
  • Innovation and Funding Models Working Group

    Chair: Poul Sørensen
    Vice Chair: Emil Pot
  • Biosimilars Working Group

    Chair: Stephanie Lane, MSD
    Vice Chair: Fabio Bisordi, Roche
  • Personalised Medicine (joint Working Group with EFPIA)

    Chair: Christine Mayer-Nicolai, Merck Group
    Vice Chair: Eelko den Breejen, F. Hoffmann-La Roche Ltd
  • BioManufacturing Working Group

    Chair: Markus Goese, Roche
    Vice Chair: Ronald Imhoff, J&J
  • Public Affairs Network

    Chair: Nathalie Stieger, Roche
    Vice Chair: Heike Galbraith, Pfizer / Mazen Elzaabi, LFB Biotechnologies
  • Regulatory & Technical Affairs Network

    Chair: Kate Beaujeux, MedImmune
    Vice Chair: Emma Dufour, AbbVie
  • Allergen Immunotherapy Task Force

    Chair: Anne Luetzhoeft Aarbogh, ALK
  • Cancer Control Task Force

    Chair: Thomas Buechele, Roche